H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Processa Pharmaceuticals with a Buy rating and $8 price target. The company is optimizing existing chemotherapeutic agents to enhance safety, tolerability and effectiveness for a wide array of cancer sufferers, the analyst tells investors in a research note. The firm says Processa aims to ameliorate patient quality of life and survival outcomes by improving upon FDA-approved, widely used oncology drugs or the cancer-killing metabolites of these drugs by altering how they are metabolized and/or distributed in the body.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCSA:
- Processa presents two abstracts at AACR 2024 including data on NGC-Cap trial
- Processa Pharmaceuticals’ Future in Jeopardy: A Dive into Its Financial Crisis and Industry Risks
- Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
- PCSA Earnings this Week: How Will it Perform?
- Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting